196 related articles for article (PubMed ID: 12325110)
1. Policy developments in regulatory approval.
Temple R
Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
[TBL] [Abstract][Full Text] [Related]
2. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
3. Regulatory considerations for determining postmarketing study commitments.
Meyer RJ
Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
[TBL] [Abstract][Full Text] [Related]
4. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
5. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
O'Neill RT
Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility probability in clinical trials.
Shao J; Chow SC
Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
8. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
9. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
10. Controlling type I error rate for fast track drug development programmes.
Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
[TBL] [Abstract][Full Text] [Related]
11. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
12. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE; Farrell AT; Pazdur R; Woodcock J
Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
[TBL] [Abstract][Full Text] [Related]
13. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
14. Postmarket surveillance. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
[TBL] [Abstract][Full Text] [Related]
16. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
17. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
[TBL] [Abstract][Full Text] [Related]
18. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
[TBL] [Abstract][Full Text] [Related]
19. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
Cocchetto DM
Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
